Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Liabilities and Shareholders Equity (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Liabilities and Shareholders Equity for 15 consecutive years, with $3.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity rose 4.9% year-over-year to $3.7 million, compared with a TTM value of $13.3 million through Sep 2025, down 40.81%, and an annual FY2024 reading of $2.8 million, down 66.66% over the prior year.
  • Liabilities and Shareholders Equity was $3.7 million for Q3 2025 at Alaunos Therapeutics, down from $4.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $128.5 million in Q1 2021 and bottomed at $2.1 million in Q1 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $45.6 million, with a median of $27.9 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity crashed 87.59% in 2024, then rose 4.9% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $94.9 million in 2021, then tumbled by 31.55% to $64.9 million in 2022, then plummeted by 87.28% to $8.3 million in 2023, then plummeted by 66.66% to $2.8 million in 2024, then skyrocketed by 35.17% to $3.7 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for TCRT at $3.7 million in Q3 2025, $4.7 million in Q2 2025, and $2.1 million in Q1 2025.